Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jiangsu Hengrui Medicine Co. Ltd.

www.hrs.com.cn

Latest From Jiangsu Hengrui Medicine Co. Ltd.

Oncology Dominates As China Drug, Biologic Approvals Surge

China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.

China Approvals

BeiGene, Hengrui Among China Firms Flexing New Oncology Muscle At ASCO

In its bid to facilitate novel treatments for some of its most prevalent cancers, China is also poised to make a dent in the global oncology market through domestically originated agents, with the number of PD-1 and CAR-T therapies under clinical development already surpassing that in the US.

ASCO China

Fifth PD-1, Zavicefta, Novel Psoriasis Ointment Among Latest China Approvals

Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.

China Approvals

Value Assessment Vexes Pharma As China Costs Soar, Prices Fall

Traditionally a low-cost manufacturing haven, China has seen pharma R&D costs increase rapidly although prices for pharmaceuticals have not gone up, forcing officials and executives to explore value assessment and market access approaches in a toughening environment.

China Health Technology Assessment
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Senior Management
  • Piaoyang Sun, Chmn.
    Lianshan Zhang, PhD, Pres., Global R&D
  • Contact Info
  • Jiangsu Hengrui Medicine Co. Ltd.
    Phone: 800 828 3900
    Lianyung Eco & Tech Development Zone
    7 Kunlunshan Rd
    , 222000
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register